KR870002846A - 백금계 항암화합물의 안정한 동결건조물의 제조방법 - Google Patents

백금계 항암화합물의 안정한 동결건조물의 제조방법 Download PDF

Info

Publication number
KR870002846A
KR870002846A KR1019860007940A KR860007940A KR870002846A KR 870002846 A KR870002846 A KR 870002846A KR 1019860007940 A KR1019860007940 A KR 1019860007940A KR 860007940 A KR860007940 A KR 860007940A KR 870002846 A KR870002846 A KR 870002846A
Authority
KR
South Korea
Prior art keywords
water soluble
glucan
weight
stabilizer
derivative
Prior art date
Application number
KR1019860007940A
Other languages
English (en)
Other versions
KR930010623B1 (ko
Inventor
가즈히로 시마
다다유끼 쓰까다
히로다네 가가와
Original Assignee
요시또시 가즈오
시오노기세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시또시 가즈오, 시오노기세이야꾸 가부시끼가이샤 filed Critical 요시또시 가즈오
Publication of KR870002846A publication Critical patent/KR870002846A/ko
Application granted granted Critical
Publication of KR930010623B1 publication Critical patent/KR930010623B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

백금계 항암화합물의 안정한 동결건조물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 글리콜레이토-시스-디아민백금(Ⅱ) 1중량부 및 안정제 0.05내지 5중량부를 주사용 증류수에 녹이고 무균적으로 여과하여 약 -80°C내지 -20°C로 냉각한 후에, 약 -3°C 또는 그 이하로 온도를 올려 같은 온도로 5내지 72시간 동안 감압하에서 승화시켜 동결건조제제를 제조하는 방법.
  2. 제 1항에 있어서, 상기 안정제가 글루칸, 수용성 비닐중합체, 폴리에틸렌글리콜 또는 그들의 혼합물임을 특징으로 하는 방법.
  3. 제 2항에 있어서, 글루칸이 수용성 중성 글루칸임을 특징으로 하는 방법.
  4. 제 2항에 있어서, 글루칸이 수용성 가공녹말 또는 그의 유도체임을 특징으로 하는 방법.
  5. 제 2항에 있어서, 글루칸이 수용성 셀룰로오즈 유도체임을 특징으로 하는 방법.
  6. 제 3항에 있어서 수용성 중성 글루칸이 덱스트란, 풀루란, 또는 아밀로즈임을 특징으로 하는 방법.
  7. 제 3항에 있어서 수용성 중성 글루칸이 덱스트란을 특징으로 하는 방법
  8. 제 4항에 있어서, 수용성 가공녹말 또는 그의 유도체가 덱스트린, 시클로데스트린, 가용성 녹말 또는 수산화에틸 녹말임을 특징으로 하는 방법.
  9. 제 5항에 있어서, 수용성 셀룰로오즈 유도체가 메틸 셀룰로오즈, 수산화에틸 셀룰로오즈, 수산화프로필메틸 셀룰로오즈 또는 카르복시메틸 셀룰로오즈 소디움염임을 특징으로 하는 방법.
  10. 제 2항에 있어서, 수용성 비닐 중합체가 폴리 비닐 알코올 또는 폴리비닐피롤리딘임을 특징으로 하는 방법
  11. 제 1항에 있어서, 상기 안정제가 상기 활성 성분 1중량부에 대하여 0.05~5중량부의 비율로 가입됨을 특징으로 하는 방법.
  12. .제 1항에 있어서, 상기 안정제가 상기 활성 성분 1중량부에 대하여 0.1~3중량부의 비율로 가입됨을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860007940A 1985-09-25 1986-09-23 백금계 항암화합물의 안정한 동결건조물의 제조방법 KR930010623B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP213180 1985-09-25
JP60-213180 1985-09-25
JP60213180A JPH0665648B2 (ja) 1985-09-25 1985-09-25 白金系抗癌物質の安定な凍結真空乾燥製剤

Publications (2)

Publication Number Publication Date
KR870002846A true KR870002846A (ko) 1987-04-13
KR930010623B1 KR930010623B1 (ko) 1993-11-02

Family

ID=16634867

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860007940A KR930010623B1 (ko) 1985-09-25 1986-09-23 백금계 항암화합물의 안정한 동결건조물의 제조방법

Country Status (9)

Country Link
US (1) US4767874A (ko)
EP (1) EP0216362B1 (ko)
JP (1) JPH0665648B2 (ko)
KR (1) KR930010623B1 (ko)
AU (1) AU593839B2 (ko)
CA (1) CA1265745A (ko)
DE (1) DE3669107D1 (ko)
DK (1) DK165356C (ko)
GB (1) GB2180839B (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100877A (en) * 1986-05-21 1992-03-31 Kuraray Co., Ltd. Platinum containing pullulan derivatives and pharmaceutical compositions comprising the same
EP0307827A3 (en) * 1987-09-15 1989-12-27 Kuraray Co., Ltd. Novel macromolecular complexes, process for producing same and medicinal use of such complexes
JPH01146826A (ja) * 1987-12-03 1989-06-08 Nippon Kayaku Co Ltd 白金化合物の凍結乾燥製剤
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
WO1990003402A1 (en) * 1988-09-27 1990-04-05 Kuraray Co., Ltd. Novel composite, process for its preparation and medicinal use thereof
DE3923270A1 (de) * 1989-07-14 1991-01-17 Medac Klinische Spezialpraep Wasserloesliche pharmazeutische metallocen-komplex-zusammensetzung
EP0516026A1 (en) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel and method of producing same
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
WO2003015521A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
WO2003075890A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
MXPA05001312A (es) * 2002-08-02 2005-08-03 Transave Inc Agregados de platino y proceso para producir los mismos.
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
ES2831305T3 (es) * 2002-10-29 2021-06-08 Insmed Inc Liposomas que comprenden un aminoglucósido para el tratamiento de infecciones pulmonares
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
WO2005089448A2 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
WO2006055352A2 (en) * 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
EP3718532A1 (en) 2005-12-08 2020-10-07 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
CN102307568B (zh) * 2009-02-04 2014-12-24 帝斯曼知识产权资产管理有限公司 白藜芦醇组合物
CN101953805B (zh) * 2010-09-29 2012-05-30 贵州益佰制药股份有限公司 一种抗肿瘤药物制剂的制备方法
EP2852391B1 (en) 2012-05-21 2021-11-17 Insmed Incorporated Systems for treating pulmonary infections
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
CN103315967B (zh) * 2013-06-18 2015-09-30 江苏奥赛康药业股份有限公司 一种含奈达铂的冻干组合物、用途及其制备方法
CN103599079B (zh) * 2013-11-25 2016-06-08 江苏奥赛康药业股份有限公司 注射用洛铂药物组合物及其制备方法
ES2755941T3 (es) 2014-05-15 2020-04-24 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118817A (en) * 1975-04-08 1976-10-19 Nippon Shinyaku Co Ltd A process for preparing absorbable steroid glycoside pharmaceutical
DE2925009A1 (de) * 1979-06-21 1981-01-08 Basf Ag Zubereitung fuer substanzen, verfahren zu deren herstellung und deren verwendung
JPS57123198A (en) * 1981-01-23 1982-07-31 Shionogi & Co Ltd Novel platinum complex
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4598091A (en) * 1983-02-18 1986-07-01 Degussa Aktiengesellschaft (1,2-diphenyl)-ethylenediamine)-platinum (II) complex compounds
JPS59222498A (ja) * 1983-06-01 1984-12-14 Shionogi & Co Ltd 新規グリコ−ル酸系白金錯体および抗悪性腫瘍剤
JPS617283A (ja) * 1984-06-20 1986-01-13 Shionogi & Co Ltd 新規白金錯体および抗悪性腫瘍剤
ATE63919T1 (de) * 1984-06-27 1991-06-15 Johnson Matthey Plc Platinkoordinationsverbindungen.
ES8801168A1 (es) * 1984-11-02 1987-02-16 Johnson Matthey Plc Procedimiento para la obtencion de un compuesto de platino para utilizar en quimioterapia del cancer.
US4737589A (en) * 1985-08-27 1988-04-12 Nippon Kayaku Kabushiki Kaisha Platinum Complexes
DK166825B1 (da) * 1985-09-06 1993-07-19 Sankyo Co Antitumor-platinkomplekser og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende disse

Also Published As

Publication number Publication date
GB2180839B (en) 1989-09-20
EP0216362A2 (en) 1987-04-01
EP0216362B1 (en) 1990-02-28
CA1265745A (en) 1990-02-13
KR930010623B1 (ko) 1993-11-02
DE3669107D1 (de) 1990-04-05
DK456886D0 (da) 1986-09-24
GB8623117D0 (en) 1986-10-29
DK165356C (da) 1993-04-05
DK165356B (da) 1992-11-16
DK456886A (da) 1987-03-26
US4767874A (en) 1988-08-30
JPS6272615A (ja) 1987-04-03
AU6310586A (en) 1987-03-26
EP0216362A3 (en) 1987-07-29
AU593839B2 (en) 1990-02-22
GB2180839A (en) 1987-04-08
JPH0665648B2 (ja) 1994-08-24

Similar Documents

Publication Publication Date Title
KR870002846A (ko) 백금계 항암화합물의 안정한 동결건조물의 제조방법
ATE133679T1 (de) Lactoneotrehalose, und ihre herstellung und verwendung
AU578857B2 (en) Production of paper and paperboard
KR870010073A (ko) 물질 fr~900506의 고체 분산 조성물
KR840009031A (ko) 니모디핀-함유 제제의 제조방법
Chazotte et al. Further studies on F1-ATPase inhibition by local anesthetics
KR870010078A (ko) 신규의 아미노산 유도체 및 그의 제조방법
KR860006479A (ko) 신규의 디사카라이드 및 트리사카라이드 유도체의 제조방법
IE40663L (en) Oxytetracycline solutions
KR920008018A (ko) 피페라진 유도체의 제조방법
NO941012L (no) Fremgangsmåte for fremstilling av nedbrytingsprodukter av stivelse med smal molekylvektsfordeling
GB1459724A (en) Method for the cold-milling of cellulose derivatives process for the production of azo compounds
GB1487980A (en) Suspension of xanthan gum
GB1404507A (en) Polysaccharide compositions
KR860006542A (ko) 안정화된 효소결합체 조성물
KR840004121A (ko) 아즈렌 유도체의 안정화 방법
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR920701183A (ko) 3-모르폴리노-시드노니민 또는 그 염들 또는 그 토우토머(tautomer)이 성질체를 함유하는 복합체들 및 그 제조방법과 이들을 함유하는 약제학적 조성물
MD679G2 (ro) Complecşi de incluziune a N-etoxicarbonil-3-morfolino-sidnoniminei sau sărurile lui cu ciclodextrinăsau cu derivaţii ei, prepararea acestora şi compoziţii farmaceutice care le conţin, procedeu de obţinere a lor şi procedeu de tratare
KR920012449A (ko) 고정화된 d-아미노산 옥시다제 및 약물 제조를 위한 이의 용도
ES424409A1 (es) Procedimiento para producir la sustancia antibiotica iso- purpuromicina.
JP2662667B2 (ja) アミラーゼｘ−２３およびその製造法
KR870009019A (ko) 이눌라제의 제조방법
Jones Pyridine Syntheses. IV. The Preparation of Some Vitamin B6 Analogs
KR870011253A (ko) 모라노린 유도체의 제법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020930

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee